Tumor angiogenesis, the formation of blood vessels that feed malignant growths, is a recognized hallmark of cancer progression, and any compound upregulating VEGF or related angiogenic mediators carries a theoretical association with the process
Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
The naturally occurring protective protein sequence originates from gastric tissue, while laboratory BPC-157 is chemically synthesised
I watched the video to help explain exactly how to do the injection
TABLE 2
